ScinoPharm Taiwan, Ltd.



Brand Quality
with Asian Advantages

ScinoPharm

ScinoPharm Taiwan, Ltd.

No.1, Nan-Ke 8th Road, Tainan Science Park, Shan-Hua, Tainan, 74144, Taiwan
TEL : 886-6-505-2888 FAX : 886-6-505-2898
Email Contact : mkt@scinopharm.com
* Purchase orders, fax to 886-6-5052889

SciAnda (Changshu) Pharmaceuticals, Ltd.

No. 16, Dong Zhou Rd., Economic Development Zone, Changshu, Jiangsu, China 215513
TEL : 86-512-5192-1000 FAX : 86-512-5192-1001

SciAnda Shanghai Biochemical Technology, Ltd.

Room 209, Block B, Uni-President Building, No. 568 Tianshan West Road, Changning District, Shanghai, 200335, China
TEL:86-021-6237-2266 FAX:86-021-3222-0867

NAFTA Area

Biddle Sawyer Corporation
21 Penn Plaza, 360 West 31st St., New York, NY 10001-2727, USA
TEL : (212) 736-1580 FAX : (212) 563-3414

ScinoPharm Taiwan Ltd., Tokyo Office

1-20-1, 6F Shinkawa
Chuo-ku, Tokyo 104-0033 Japan
Tel: 81-3-6699-8073*12
Fax: 81-3-3553-8602

EXCEEDING EXPECTATIONS

ScinoPharm Taiwan offers a wide array of process R&D services and Active Pharmaceutical Ingredients (API) manufacturing capabilities designed to satisfy customers' exact requirements and facilitate their rapid market introductions.

Combined with a large and cost effective R&D infrastructure and global regulatory capabilities, ScinoPharm delivers integrated solutions in synthesizing complex molecules, including high potent and cytotoxic compounds, ensuring fast time-to-market.

Since our inception in 1997, we have successfully delivered numerous full-scale research and manufacturing projects for our multi-national customers involving the development of non-infringing process patents and related analytical R&D, regulatory compliance, quality and environmental management services.

In accordance with our long-term business strategy, ScinoPharm continues to pursue strategic alliances to enhance its position as a developer and manufacturer of innovative products with high added value. Combined with our proficient API production and injectable capacity, ScinoPharm can successfully create a niche for generic sterile formulations.

We will continue to exceed customer expectations and grow our competitive advantages through the following:

- **Constant customer-centric focus**
- **Continued investment in the latest technologies and equipment for all areas of our operations**
- **Constant additions to our platform technologies**

We will strive to maintain our expertise and market leadership in oncology APIs and services while carefully developing new niche areas using our expanded capabilities in both Taiwan and China.

INNOVATING SOLUTIONS

ScinoPharm delivers high-value solutions to its customers with speed and flexibility through a full range of services from development to commercialization, in addition to cGMP manufacture of materials for clinical trials. Our success is built on our growing partnerships with customers around the world.

Supply of Generic APIs

ScinoPharm can provide the technical and manufacturing services required for early development of generic APIs with products delivered years before originator patents expire. Leveraging on our proprietary technologies and non-infringing processes, our strong product portfolio is comprised of higher-valued APIs and advanced intermediates. Our capability in processing highly potent substances is one of our competitive strengths. Our customers can always expect a reliable API supply from us with consistent quality and timely Drug Master File (DMF) registration.

Custom Process Research Services

Drawing on our diversified technical know-how, ScinoPharm can provide custom process development for early phase API activities from small to medium-sized molecules by implementing Quality by Design (QbD) methods and critical process parameters studies. We can also provide validated cGMP facilities for the synthesis of experimental materials, including chemical building blocks, required for clinical trials and IND studies. Working closely with clients, our customer service team helps accelerate time-to-market with effective project management and focused initiatives.

Custom Manufacturing Services

Our integrated custom research and manufacturing services enable efficient technology transfer and project administration, which in turn helps customers accelerate their drug development and supply projects. Recognized for our stringent Intellectual Property Protection and Quality Compliance, ScinoPharm is partnering with leading pharmaceutical companies for industrial manufacturing of new and existing drugs. We provide customers a competitive and cost-advantaged service with brand quality, including IP and EH&S assurances.

Oncology/High Potency Injectable manufacturing Services

Adopting state-of-the art design and isolator-based aseptic filling systems, ScinoPharm is read to partner with customers by offering high quality injectable products. Our new injectable plant has been built to meet global GMP standards for the production of oncology and peptide drugs, in particular for those come with specific requirements. Either using in-house APIs or the APIs from third party, ScinoPharm can be an injectable product provider starting formulation development through the filing of ANDA with FDA.

BUILDING CAPABILITIES

We have core competences in four areas and ensure their successful integration via our Project Management system. By combining our Western cGMP operations in Taiwan and China, our technical staff can provide a quality API supply at competitive prices. We strive to be the first to launch tough-to-make products.

Process Development and Custom Synthesis Services

ScinoPharm possesses a full range of chemistry capabilities and extensive experience in synthesizing complex molecules. Depending on individual requirements, we develop new synthetic routes, or scale up and optimize processes based on the customer's technology. Our synthetic studies include structured Design of Experiment (DoE) methods used to identify optimal conditions, factors that most influence the results, as well as interactions and synergies between factors. In addition, process validation studies are conducted using parallel synthesizers and multiple reactors to define stress limits of the proposed plant process. Appropriate computer software programs are used to assist in the design of the experiments and in the analysis of experimental results.

Analytical R&D, Quality and Regulatory Services

ScinoPharm provides a full spectrum of analytical services, documentation and regulatory support. Our skilled analytical specialists, supported by advanced analytical instruments, can manage complex tasks posed by tightening impurity requirements from regulatory agencies. To ensure consistency in quality, we employ Design Space Concepts that allow us to understand the impact of any proposed change based on careful scientific lab studies done before they are attempted in the manufacturing process. DoE is one of the tools used to achieve this objective. Customers can benefit additionally from our supplementary reference standards such as polymorphs to facilitate their formulation developments.



Full-scale Manufacturing

Production of APIs is typically the most technically complex element of the pharmaceutical supply chain, especially when it involves high-potency and cytotoxic drug substances. ScinoPharm's multiple facilities, approved by various regulatory authorities across the world including the US FDA, are operated in strict conformity to international cGMP guidelines as well as to local safety and environment protection standards both in Taiwan and China. Our quality manufacturing is further bolstered by the deployment of computer-controlled process and utilities systems. With production scales ranging from kilograms to multi-tons, we can offer flexible manufacturing alternatives that maximize cost efficiencies.

Peptide APIs and Related Building Block Technologies

ScinoPharm provides comprehensive peptide synthesis technologies with full analytical and regulatory support. With our knowledge and expertise in solution phase, solid phase, polyethyleneglycol (PEG) and segmental synthesis, ScinoPharm can design and develop higher yield processes for larger-scale peptides that are scalable, faster, and more cost effective.

RESPECTED CREDENTIALS

ScinoPharm adheres to the latest ICH cGMP guidelines. The company has successfully passed many government agency inspections, including: Taiwan DOH, US FDA, EDQM, Australia TGA, Japan PMDA, EMA, Korean KFDA and Mexican COFEPRIS.

ScinoPharm recognizes that simply providing products or services is not enough in today's litigious and liability-focused world. The company assures our customers of our:

- Process R&D and manufacturing operations operated in accordance with industry best practices
- Compliance with all intellectual property protection requirements and assurances that our technology will not infringe existing patents
- Adherence to international quality and regulatory practices; compliance is verified by US FDA inspections and by numerous yearly customer audits
- Careful monitoring and response to all environmental, health and safety issues for our employees and our communities
- Commitment to a sustainable coexistence with our environment, ensuring that all operations are energy and waste efficient

COMPETITIVE ADVANTAGES

ScinoPharm operates its API business with a global perspective and understands that our customers require consistent and reliable value-added solutions for increased productivity and competitiveness. As we look to our next stage of growth and the requirements of an ever-changing marketplace, we will broaden our strategy to further enhance our offerings.



Global Network

In order to fulfill increasing demand from multi-national pharmaceutical companies as well as to expand into a new market in China, ScinoPharm has been expanding our process development and manufacturing capabilities by adding significant production and technical capacity in China at our Changshu site, which is also US FDA-approved for intermediates and high potency APIs. The Changshu site features a combination of proximity to the end market in China and world-class strengths in process R&D and technical capability, functioning as a gateway between the Chinese and global markets.

We will continue to expand our international presence by establishing strategic partnerships with brand and generic drug companies who wish to distribute their products into the rapidly growing markets of China, Japan, India, South Korea, etc.

Vertical Integration

Being one of the top suppliers of high potent/ oncological worldwide to regulated markets, ScinoPharm is poised to provide the service to customers with high potent/ oncological injectable drug products. With the new injectable plant completion in Tainan campus in Taiwan in 2017 and together with well-established API capability, ScinoPharm is able to offer high quality pharmaceuticals from API to final dosage form under one roof with greater flexibility, reliability, and efficiency.

Service Specialty and Uniqueness

Positioned currently as a specialist developer and producer of highly potent and cytotoxic compounds and injectables, ScinoPharm has emerged as a leading supplier of oncology APIs where technological and facility barriers are high. In addition, the in-depth international pharmaceutical and regulatory experience of our senior management team has allowed us to create an API business environment similar to the much larger multi-nationals, as we fully understand their stringent and cost-effective requirements. Our willingness to work closely with selected customers on exclusive or semi-exclusive deals adds to our offerings. Furthermore for communication efficiency, English is our primary business language.

Proactive Patent Approach

In today's knowledge-based global economy, our success will depend, in part, on our ability to obtain and enforce patents while not infringing the proprietary rights of others. We have a policy of aggressively promoting patent fillings for our innovative products and processes developed in the course of our R&D activities and we intend to grow our business by continually expanding these intellectual property assets.

SUSTAINABLE DEVELOPMENT

ScinoPharm is a socially and environmentally responsible business. We recognize our corporate and social responsibilities to our shareholders, customers, suppliers, employees and other stakeholders and are committed to conducting our business in a manner that achieves sustainable growth while fulfilling legal and moral obligations. We believe that our business can make a positive contribution to society and the environment by managing our activities with care and by working with responsible organizations that promote social and environmental causes.

ScinoPharm strives to maintain core corporate values of ethical management and is conscientious about complying with governmental policies, taking the initiative in response to laws and regulations relating to environmental, social, and safety issues. Our considerations and actions in response to the environmental, social, and economical challenges we face are comprehensive and in-depth. Though our overall strategies, indicators, programs for implementation, and related measures are dictated by current technologies and resources and our need to comply with current laws and regulations, we are still able to carry out our corporate goals of sustainability, social responsibility, and integrity.

The Company has established an "Occupational Safety and Health Committee" and a "Sustainable Management Committee" as a tandem approach for environmental protection. The former committee was established in accordance with the Procedures for Management of Occupational Safety and Health, and serves as our highest EHS decision-making authority; the latter committee was established to promote policies relating to environmental protection, health and safety, energy conservation, water conservation, and management of greenhouse gases, to enhance ScinoPharm's sustainable competitiveness. We propose annual sustainable management programs and review past implementations to provide a basis for internal reviews.

Rooted in the company's core values, our culture has developed dynamically around a customer-centric focus by our staff, who are at the heart of the company's continued success. Our employees are provided with ample opportunities for professional and personal growth. We believe that our empowered and committed staff is the key to providing services unique to our customers.

At ScinoPharm, we are guided by shared values of business ethics, commitment to quality and safety, equal partnership, diversity of workforce, and enduring innovation. Through these core values, our people are inspired to do more than just the right things: we encourage them to constantly look for ways to make our services better.

DRIVING FOR FOCUSED GROWTH



Our strategic expansion into China, along with our widening alliances with industry partners, enables ScinoPharm to support both global and local customers with a reliable supply of quality APIs, drug products, and cost-competitive contract research and manufacturing solutions.

ScinoPharm is evolving into a full scope specialty pharma based on our core competency of strong R&D and cGMP manufacturing in difficult-to-make APIs. This vertical integration will allow ScinoPharm to provide customers a comprehensive range of API supply through injectable formulation CMO services. The sterile fill and finish environment of the injectable plant complies with the highest standards per international cGMP guidelines.

Through our expanded business in the global marketplace, strong R&D capacity, insistence on quality, and expansive global sales network, ScinoPharm committed to innovative and cost-effective technical services while maintaining the utmost standards for regulatory compliance and environmental management. Our promise is to deliver consistent results and substantial benefits for all of our partners.